GlassScriptPhysician profile
Yen D Nieman
NPI 1295825784
$3,745.69
in general payments reported to CMS, 2019-2025
25 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $392 · 2021: $431 · 2022: $451 · 2023: $577 · 2024: $832 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044 · Long Term Medical Supply Or Device Loan: $64.25 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,044.31 |
| Long Term Medical Supply Or Device Loan | $64.25 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $953.08 | 2022-2025 | |
| Rxsight INC | $552.00 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Alcon Vision LLC | $517.46 | 2019-2025 | Lensx, Clareon Panoptix Pro |
| Allergan, INC. | $332.80 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $204.82 | 2021-2022 | |
| Biotissue Holdings INC. | $126.10 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $119.95 | 2020 | |
| Mallinckrodt Enterprises LLC | $119.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $108.67 | 2019-2021 | |
| Optos, INC. | $98.67 | 2021 | |
| Bausch & Lomb Americas INC. | $92.60 | 2023-2025 | Vyzulta, Miebo |
| Dompe US, INC. | $91.52 | 2020-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $91.23 | 2024 | Xdemvy |
| Kowa Research Institute, INC. | $86.57 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $64.25 | 2023 | Cirrus Hd-Oct |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $51.01 | 2024-2025 | |
| Amgen INC. | $36.78 | 2024-2025 | Tepezza |
| Rayner Intraocular Lenses Limited | $22.74 | 2024 | Rayone Spheric, Omidria, Rayone Emv |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.70 | 2020 | |
| Oyster Point Pharma, INC. | $15.41 | 2022 | |
| Shire North American Group INC | $14.83 | 2019 | |
| Tearlab Corp | $14.81 | 2023 | Tearlab Osmolarity System |
| Thea Pharma INC. | $14.38 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yen Nieman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.